16,855 Shares in Bioverativ Inc (BIVV) Purchased by Hendershot Investments Inc.
Hendershot Investments Inc. purchased a new position in shares of Bioverativ Inc (NASDAQ:BIVV) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 16,855 shares of the biotechnology company’s stock, valued at approximately $962,000.
Several other institutional investors have also recently modified their holdings of BIVV. Frontier Capital Management Co. LLC bought a new stake in shares of Bioverativ during the 3rd quarter worth approximately $54,653,000. First Trust Advisors LP bought a new stake in shares of Bioverativ during the 3rd quarter worth approximately $38,238,000. First Quadrant L P CA bought a new stake in shares of Bioverativ during the 3rd quarter worth approximately $19,310,000. Peregrine Capital Management LLC bought a new stake in shares of Bioverativ during the 3rd quarter worth approximately $17,643,000. Finally, Nationwide Fund Advisors bought a new stake in shares of Bioverativ during the 3rd quarter worth approximately $17,617,000. 92.93% of the stock is owned by institutional investors.
In related news, Director Louis J. Paglia acquired 2,000 shares of the stock in a transaction that occurred on Monday, August 7th. The stock was acquired at an average cost of $59.70 per share, for a total transaction of $119,400.00. Following the transaction, the director now directly owns 5,056 shares in the company, valued at $301,843.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Brian S. Posner purchased 1,000 shares of the firm’s stock in a transaction on Wednesday, August 9th. The stock was acquired at an average price of $59.19 per share, with a total value of $59,190.00. Following the completion of the transaction, the director now owns 6,693 shares in the company, valued at approximately $396,158.67. The disclosure for this purchase can be found here.
A number of analysts have recently weighed in on BIVV shares. Zacks Investment Research raised shares of Bioverativ from a “hold” rating to a “strong-buy” rating and set a $73.00 price target for the company in a report on Tuesday, July 25th. Royal Bank Of Canada started coverage on shares of Bioverativ in a report on Thursday, September 14th. They set a “sector perform” rating and a $59.00 price target for the company. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $71.00 price target on shares of Bioverativ in a report on Monday, October 23rd. Evercore ISI started coverage on shares of Bioverativ in a report on Wednesday, August 16th. They set an “in-line” rating and a $58.00 price target for the company. Finally, Cowen and Company raised shares of Bioverativ from a “market perform” rating to an “outperform” rating in a report on Monday, July 10th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $61.73.
Bioverativ Inc (NASDAQ:BIVV) traded up $0.36 during mid-day trading on Friday, reaching $54.01. 1,119,174 shares of the company were exchanged, compared to its average volume of 1,110,101. Bioverativ Inc has a twelve month low of $40.00 and a twelve month high of $64.41.
Bioverativ (NASDAQ:BIVV) last released its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.55 by $0.25. The business had revenue of $291.60 million during the quarter, compared to analysts’ expectations of $285.45 million. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. Bioverativ’s quarterly revenue was up 27.2% on a year-over-year basis. analysts anticipate that Bioverativ Inc will post 2.45 earnings per share for the current year.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.